Metoprolol succinate interactions
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol Succinate Interactions: A Comprehensive Overview
Introduction to Metoprolol Succinate
Metoprolol succinate is a cardioselective beta-blocker commonly used to manage hypertension, angina, and heart failure. It is available in extended-release formulations, which provide a consistent release of the drug over time, ensuring stable plasma concentrations and therapeutic effects .
Interaction with Palmitic Acid
Binding Site Displacement
Research has shown that palmitic acid can significantly impact the binding of metoprolol succinate to bovine serum albumin (BSA). When palmitic acid is present, it displaces metoprolol succinate from its binding sites on BSA, leading to an increased free fraction of the drug in the plasma. This displacement effect is further amplified in the presence of other drugs like ranitidine and diazepam, which also bind to BSA .
Interaction with Paroxetine
Pharmacokinetic Changes
Paroxetine, a CYP2D6 inhibitor, has been found to interact with both immediate-release and extended-release formulations of metoprolol. This interaction results in a significant increase in the plasma concentration of metoprolol, particularly affecting the R-enantiomer. The stereoselective metabolism of metoprolol is altered, potentially leading to enhanced beta-blockade and reduced cardioselectivity .
Combination with Telmisartan
Pharmacokinetics and Safety
When metoprolol succinate is combined with telmisartan, an angiotensin receptor blocker, there appears to be no significant pharmacokinetic interaction. The combination therapy has shown improved antihypertensive effects without additive toxicity, suggesting it is a safe and effective treatment option for managing hypertension .
Combination with Entresto
Cardiac and Coagulation Function
Combining metoprolol succinate with Entresto (sacubitril/valsartan) has demonstrated significant improvements in cardiac function and coagulation parameters in patients with congestive heart failure. This combination therapy enhances left ventricular ejection fraction (LVEF) and reduces oxidative stress and blood coagulation markers, indicating a beneficial effect on ventricular remodeling and overall cardiac health .
Efficacy in Special Populations
Diabetic Patients with Heart Failure
In patients with diabetes and chronic heart failure, metoprolol succinate has been shown to reduce the risk of hospitalization for heart failure significantly. The drug is well-tolerated in diabetic patients, providing similar survival benefits as seen in non-diabetic patients .
Pediatric Hypertension
Extended-release metoprolol succinate has also been evaluated in children aged 6 to 16 years with hypertension. The drug effectively reduces both systolic and diastolic blood pressure at various dosages, with a good safety profile and no serious adverse events reported .
Conclusion
Metoprolol succinate interacts with various substances, including palmitic acid and paroxetine, which can alter its pharmacokinetic profile and therapeutic effects. Combination therapies with drugs like telmisartan and Entresto show promise in enhancing treatment outcomes for hypertension and heart failure. Additionally, metoprolol succinate is effective and well-tolerated in both diabetic patients with heart failure and hypertensive children, making it a versatile option in cardiovascular therapy.
Sources and full results
Most relevant research papers on this topic